Kalvista Pharmaceuticals Inc (NASDAQ:KALV) — Market Cap & Net Worth
Market Cap & Net Worth: Kalvista Pharmaceuticals Inc (KALV)
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has a market capitalization of $820.37 Million ($820.37 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10024 globally and #2561 in its home market, demonstrating a 39.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kalvista Pharmaceuticals Inc's stock price $26.65 by its total outstanding shares 50546293 (50.55 Million). Analyse KALV operating cash flow to see how efficiently the company converts income to cash.
Kalvista Pharmaceuticals Inc Market Cap History: 2015 to 2026
Kalvista Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $2.56 Billion to $1.35 Billion (-6.32% CAGR).
Index Memberships
Kalvista Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.03% | #272 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1004 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.05% | #162 of 263 |
Weight: Kalvista Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kalvista Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kalvista Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
52.70x
Kalvista Pharmaceuticals Inc's market cap is 52.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $357.36 Million | $2.13 Million | -$11.44 Million | 167.54x | N/A |
| 2017 | $492.83 Million | $1.50 Million | -$18.60 Million | 327.68x | N/A |
| 2018 | $998.29 Million | $8.39 Million | -$15.80 Million | 118.93x | N/A |
| 2019 | $900.23 Million | $16.13 Million | -$20.82 Million | 55.82x | N/A |
| 2020 | $959.87 Million | $12.69 Million | -$29.12 Million | 75.64x | N/A |
| 2021 | $668.73 Million | $12.69 Million | -$46.24 Million | 52.70x | N/A |
Competitor Companies of KALV by Market Capitalization
Companies near Kalvista Pharmaceuticals Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Kalvista Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Kalvista Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Kalvista Pharmaceuticals Inc's market cap moved from $2.56 Billion to $ 1.35 Billion, with a yearly change of -6.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.35 Billion | +65.02% |
| 2025 | $816.32 Million | +90.67% |
| 2024 | $428.13 Million | -30.86% |
| 2023 | $619.19 Million | +81.21% |
| 2022 | $341.69 Million | -48.90% |
| 2021 | $668.73 Million | -30.33% |
| 2020 | $959.87 Million | +6.63% |
| 2019 | $900.23 Million | -9.82% |
| 2018 | $998.29 Million | +102.56% |
| 2017 | $492.83 Million | +37.91% |
| 2016 | $357.36 Million | -86.05% |
| 2015 | $2.56 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Kalvista Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $820.37 Million USD |
| MoneyControl | $820.37 Million USD |
| MarketWatch | $820.37 Million USD |
| marketcap.company | $820.37 Million USD |
| Reuters | $820.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more